Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2007

01.01.2007 | Original article

Bone involvement in patients with lymphoma: the role of FDG-PET/CT

verfasst von: Niklaus G. Schaefer, Klaus Strobel, Christian Taverna, Thomas F. Hany

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the diagnostic impact and clinical significance of FDG-avid bone lesions detected by FDG-PET/CT in patients with lymphoma.

Methods

The study population comprised 50 consecutive patients (mean age 41.7±15.5 years; 27 female, 23 male; 41 staging, 9 restaging) with Hodgkin’s disease (n=22) or aggressive non-Hodgkin’s lymphoma (n=28) in whom FDG-avid bone lesions were detected by FDG-PET/CT. All patients had either direct biopsy of the FDG-avid bone lesion (n=18), standard bone marrow biopsy at the iliac crest (BMB; n=43) or both procedures (n=11). In 15 patients, additional MRI of the bone lesions was performed. All patients underwent FDG-PET/CT after the end of treatment. All CT images of FDG-PET/CT scans were analysed independently regarding morphological osseous changes and compared with FDG-PET results.

Results

In the 50 patients, 193 FDG-avid lesions were found by PET/CT. The mean standardised uptake value was 6.26 (±3.22). All direct bone biopsies (n=18) of the FDG-avid lesions proved the presence of lymphomatous infiltration. BMB (n=43) was positive in 12 patients (27.9%). In CT, 32 of 193 (16.6%) lesions were detected without the PET information. No additional morphological bone infiltration was detected on CT compared with FDG-PET. All morphological bone alterations on CT scans persisted after the end of therapy. Additional PET/CT information regarding uni- or multifocal bone involvement resulted in lymphoma upstaging in 21 (42%) patients compared with the combined information provided by CT and BMB.

Conclusion

In patients with FDG-avid bone lesions, FDG-PET is superior to CT alone or in combination with unilateral BMB in detecting bone marrow involvement, leading to upstaging in a relevant proportion of patients.
Literatur
1.
Zurück zum Zitat Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721–8.PubMedCrossRef Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721–8.PubMedCrossRef
2.
Zurück zum Zitat Buchmann I, Moog F, Schirrmeister H, Reske SN. Positron emission tomography for detection and staging of malignant lymphoma. Recent Results Cancer Res 2000;156:78–89.PubMed Buchmann I, Moog F, Schirrmeister H, Reske SN. Positron emission tomography for detection and staging of malignant lymphoma. Recent Results Cancer Res 2000;156:78–89.PubMed
3.
Zurück zum Zitat Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002;43:1018–27.PubMed Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002;43:1018–27.PubMed
4.
Zurück zum Zitat Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340–6.PubMed Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340–6.PubMed
5.
Zurück zum Zitat Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603–9.PubMed Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603–9.PubMed
6.
Zurück zum Zitat Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958–63.PubMed Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958–63.PubMed
7.
Zurück zum Zitat Park YH, Kim S, Choi SJ, Ryoo BY, Yang SH, Cheon GJ, et al. Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone. Ann Oncol 2005;16:1401–2.PubMedCrossRef Park YH, Kim S, Choi SJ, Ryoo BY, Yang SH, Cheon GJ, et al. Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone. Ann Oncol 2005;16:1401–2.PubMedCrossRef
8.
Zurück zum Zitat Park YH, Choi SJ, Ryoo BY, Kim HT. PET imaging with F-18 fluorodeoxyglucose for primary lymphoma of bone. Clin Nucl Med 2005;30:131–4.PubMedCrossRef Park YH, Choi SJ, Ryoo BY, Kim HT. PET imaging with F-18 fluorodeoxyglucose for primary lymphoma of bone. Clin Nucl Med 2005;30:131–4.PubMedCrossRef
9.
Zurück zum Zitat Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer 2002;94:1522–31.PubMedCrossRef Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer 2002;94:1522–31.PubMedCrossRef
10.
Zurück zum Zitat A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–94. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–94.
11.
Zurück zum Zitat Jost LM, Kloke O, Stahel RA. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin’s lymphoma. Ann Oncol 2005;16 Suppl 1:i58–9.PubMedCrossRef Jost LM, Kloke O, Stahel RA. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin’s lymphoma. Ann Oncol 2005;16 Suppl 1:i58–9.PubMedCrossRef
12.
Zurück zum Zitat Jost LM, Stahel RA. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin’s disease. Ann Oncol 2005;16 Suppl 1:i54–5.PubMedCrossRef Jost LM, Stahel RA. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin’s disease. Ann Oncol 2005;16 Suppl 1:i54–5.PubMedCrossRef
13.
Zurück zum Zitat Macintyre EA, Vaughan Hudson B, Linch DC, Vaughan Hudson G, Jelliffe AM, et al. The value of staging bone marrow trephine biopsy in Hodgkin’s disease. Eur J Haematol 1987;39:66.PubMedCrossRef Macintyre EA, Vaughan Hudson B, Linch DC, Vaughan Hudson G, Jelliffe AM, et al. The value of staging bone marrow trephine biopsy in Hodgkin’s disease. Eur J Haematol 1987;39:66.PubMedCrossRef
14.
Zurück zum Zitat Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood 2005;105:1875–80.PubMedCrossRef Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood 2005;105:1875–80.PubMedCrossRef
15.
Zurück zum Zitat Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V. Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. German Hodgkin’s Lymphoma Study Group. J Clin Oncol 1995;13:403.PubMed Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V. Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. German Hodgkin’s Lymphoma Study Group. J Clin Oncol 1995;13:403.PubMed
16.
Zurück zum Zitat Howard MR, Taylor PR, Lucraft HH, Taylor MJ, Proctor SJ. Bone marrow examination in newly diagnosed Hodgkin’s disease: current practice in the United Kingdom. Br J Cancer 1995;71:210–2.PubMed Howard MR, Taylor PR, Lucraft HH, Taylor MJ, Proctor SJ. Bone marrow examination in newly diagnosed Hodgkin’s disease: current practice in the United Kingdom. Br J Cancer 1995;71:210–2.PubMed
17.
Zurück zum Zitat Foucar K, McKenna RW, Frizzera G, Brunning RD. Bone marrow and blood involvement by lymphoma in relationship to the Lukes-Collins classification. Cancer 1982;49:888.PubMedCrossRef Foucar K, McKenna RW, Frizzera G, Brunning RD. Bone marrow and blood involvement by lymphoma in relationship to the Lukes-Collins classification. Cancer 1982;49:888.PubMedCrossRef
18.
Zurück zum Zitat Conlan MG, Bast, M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin’s lymphoma: The clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990;8:1163.PubMed Conlan MG, Bast, M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin’s lymphoma: The clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990;8:1163.PubMed
19.
Zurück zum Zitat Nakamoto Y, Cohade C, Tatsumi M, Hammoud D, Wahl RL. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology 2005;237:627–34.PubMedCrossRef Nakamoto Y, Cohade C, Tatsumi M, Hammoud D, Wahl RL. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology 2005;237:627–34.PubMedCrossRef
20.
Zurück zum Zitat Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244–7.PubMedCrossRef Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244–7.PubMedCrossRef
21.
Zurück zum Zitat Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407–13.PubMed Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407–13.PubMed
22.
Zurück zum Zitat Mengiardi B, Honegger H, Hodler J, Exner UG, Csherhati MD, Bruhlmann W. Primary lymphoma of bone: MRI and CT characteristics during and after successful treatment. Am J Roentgenol 2005;184:185–92. Mengiardi B, Honegger H, Hodler J, Exner UG, Csherhati MD, Bruhlmann W. Primary lymphoma of bone: MRI and CT characteristics during and after successful treatment. Am J Roentgenol 2005;184:185–92.
23.
Zurück zum Zitat Stiglbauer R, Augustin I, Kramer J, Schurawitzki H, Imhof H, Radaszkiewicz T. MRI in the diagnosis of primary lymphoma of bone: correlation with histopathology. J Comput Assist Tomogr 1992;16:248–53.PubMedCrossRef Stiglbauer R, Augustin I, Kramer J, Schurawitzki H, Imhof H, Radaszkiewicz T. MRI in the diagnosis of primary lymphoma of bone: correlation with histopathology. J Comput Assist Tomogr 1992;16:248–53.PubMedCrossRef
24.
Zurück zum Zitat Kellenberger CJ, Miller SF, Khan M, Gilday DL, Weitzman S, Babyn PS. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol 2004;14:1829–41.PubMedCrossRef Kellenberger CJ, Miller SF, Khan M, Gilday DL, Weitzman S, Babyn PS. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol 2004;14:1829–41.PubMedCrossRef
25.
Zurück zum Zitat Mink J. Percutaneous bone biopsy in the patient with known or suspected osseous metastasis. Radiology 1986;161:191–4.PubMed Mink J. Percutaneous bone biopsy in the patient with known or suspected osseous metastasis. Radiology 1986;161:191–4.PubMed
26.
Zurück zum Zitat Kaim AH, Burger C, Ganter CC, Goerres GW, Kamel E, Weishaupt D, et al. PET-CT-guided percutaneous puncture of an infected cyst in autosomal dominant polycystic kidney disease: case report. Radiology 2001;221:818–21.PubMedCrossRef Kaim AH, Burger C, Ganter CC, Goerres GW, Kamel E, Weishaupt D, et al. PET-CT-guided percutaneous puncture of an infected cyst in autosomal dominant polycystic kidney disease: case report. Radiology 2001;221:818–21.PubMedCrossRef
Metadaten
Titel
Bone involvement in patients with lymphoma: the role of FDG-PET/CT
verfasst von
Niklaus G. Schaefer
Klaus Strobel
Christian Taverna
Thomas F. Hany
Publikationsdatum
01.01.2007
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0238-8

Weitere Artikel der Ausgabe 1/2007

European Journal of Nuclear Medicine and Molecular Imaging 1/2007 Zur Ausgabe